Coronavirus (COVID-19) Update - We are reopening slowly while keeping your safety in mind.
Click here to learn more.
A Phase I Study of Entinostat in combination with Enzalutamide for treatment of patients with castration-resistant prostate cancer (CRPC)
Candidates: Patients with Castration-Resistant Prostate Cancer will participate in this phase I study by taking enzalutamide daily and the study drug Entinostat once every 7 days.
Jinqing Lin, MD